genOway

ALGEN.PAPre-clinical

genOway is a leading provider of genetically modified preclinical models, specializing in humanized mice, rats, and cell lines to improve the translational predictability of drug discovery and development. The company collaborates extensively with top pharmaceutical firms, biotechs, and academic institutions, with its models featured in over 600 scientific publications. Its strategic focus is on immuno-oncology, immunology, and inflammation, offering both off-the-shelf catalog models and bespoke solutions to address specific research needs.

Market Cap

$35.3M

ALGEN.PA · Stock Price

USD 2.480.92 (-27.17%)

Historical price data

AI Company Overview

Technology Platform

Expertise in genetic engineering to create humanized mouse, rat, and cell line models, including immunodeficient host platforms (BRGSF) for human immune system engraftment and targeted humanization of specific genes (e.g., PD-1, CD3, CCR8) for predictive preclinical research.

Opportunities

Growth is driven by increasing demand for complex humanized models in immuno-oncology and immunology.

Opportunities include expanding its catalog for emerging targets, deepening strategic partnerships with large pharma to become an embedded R&D partner, and geographic expansion in key biopharma markets like the US and Asia.

Risk Factors

Key risks include long-term technological disruption from non-animal testing methods, intense competition from larger, integrated CROs, operational risks associated with breeding specialized animal colonies, and potential intellectual property disputes in the genetically engineered model space.

Competitive Landscape

genOway competes with large model providers like The Jackson Laboratory and Taconic Biosciences, and full-service CROs like Charles River Laboratories. Its differentiation lies in its deep scientific collaboration model, focus on complex 'double-humanized' models for specific pathways, and its validated position as a partner to 17 of the Top 20 pharmaceutical companies.